Predicting the survival benefit of cardiac resynchronization therapy with defibrillator function for non-ischemic heart failure-Role of the Goldenberg risk score.
cardiac resynchronization therapy
implantable cardioverter defibrillator
non-ischemic heart failure
risk score
sudden cardiac death
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
05
10
2022
accepted:
23
12
2022
entrez:
27
1
2023
pubmed:
28
1
2023
medline:
28
1
2023
Statut:
epublish
Résumé
Primary prevention of sudden cardiac death (SCD) in non-ischemic heart failure (HF) patients remains a topic of debate at cardiac resynchronization therapy (CRT) implantation requiring individual risk assessment. Using the Goldenberg SCD risk score, we aimed to predict, which non-ischemic HF patients will benefit from the addition of an implantable cardioverter defibrillator (ICD) to CRT at long-term. Between 2000 and 2018 non-ischemic HF patients undergoing CRT implantation were collected into our retrospective registry. The Goldenberg risk score (GRS) was calculated by the presence of atrial fibrillation, New York Heat Association (NYHA) class > 2, age > 70 years, blood urea nitrogen > 26 mg/dl and QRS > 120 ms. The primary endpoint was all-cause mortality, heart transplantation or left ventricular assist device implantation. From 667 patients, 347 (52%) underwent cardiac resynchronization therapy-pacemaker (CRT-P), 320 (48%) cardiac resynchronization therapy-defibrillator (CRT-D) implantations. During the median follow up time of 4.3 years, 306 (46%) patients reached the primary endpoint (CRT-D 37% vs. CRT-P 63%; In our non-ischemic cohort, patients with low GRS showed a clear long-term mortality benefit by adding ICD to CRT, however, in high-risk patients no further benefit could be observed.
Identifiants
pubmed: 36704467
doi: 10.3389/fcvm.2022.1062094
pmc: PMC9871919
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1062094Informations de copyright
Copyright © 2023 Merkel, Schwertner, Behon, Kuthi, Veres, Osztheimer, Papp, Molnár, Zima, Gellér, Kosztin and Merkely.
Déclaration de conflit d'intérêts
AK receives consulting fees from Medtronic and Biotronik, and receives payment or honoraria for lectures from Novartis, Bayer, Boehringer Ingelheim, Astra Zeneca, Medtronic Biotronik, and Boston Scientific. BM receives grants or has contracts with Abbott, Astra Zeneca, Argint International, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, CSL Behring, Daiichi Sankyo, Cerenis Therapeutics SA DUKE Clinical Institut, Eli Lilly, Medtronic, Novartis, Terumo, St. Jude, Zoll and VIFOR Pharma, and receives lecture fees from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, and Novartis. LG receives lecture fees from Biotronik, Medtronic, Johnson & Johnson Medical, and Abbott outside the submitted work. EZ reports lecture and advisory fees from Biotronik, Medtronic, Boston Scientific, and Zoll Medical, outside the submitted work. RP reports lecture fees from Biotronik, Medtronic, and Abbott outside the submitted work. LM reports lecture fees from Biotronik, Medtronic, and Abbott outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Am Coll Cardiol. 2012 Jun 5;59(23):2075-9
pubmed: 22651863
JACC Heart Fail. 2019 Aug;7(8):717-724
pubmed: 31302052
Europace. 2016 Aug;18(8):1187-93
pubmed: 26566940
Europace. 2017 Apr 1;19(4):660-664
pubmed: 28431077
Circulation. 2014 Dec 23;130(25):2278-86
pubmed: 25301831
N Engl J Med. 2002 Mar 21;346(12):877-83
pubmed: 11907286
N Engl J Med. 2004 May 20;350(21):2140-50
pubmed: 15152059
Europace. 2019 May 1;21(5):754-762
pubmed: 30590500
Circulation. 2011 Oct 4;124(14):1527-36
pubmed: 21900084
N Engl J Med. 2009 Oct 1;361(14):1329-38
pubmed: 19723701
Eur J Heart Fail. 2020 Dec;22(12):2349-2369
pubmed: 33136300
Heart Rhythm. 2009 Apr;6(4):468-73
pubmed: 19324304
Eur J Heart Fail. 2014 Dec;16(12):1323-30
pubmed: 25379962
Eur Heart J. 2022 Jul 14;43(27):2591-2599
pubmed: 35366320
J Am Coll Cardiol. 2008 Jan 22;51(3):288-96
pubmed: 18206738
Eur Heart J. 2021 Sep 14;42(35):3427-3520
pubmed: 34455430
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
Eur Heart J. 2021 May 1;42(17):1676-1684
pubmed: 33417692
N Engl J Med. 2004 May 20;350(21):2151-8
pubmed: 15152060
Europace. 2018 Nov 1;20(11):1804-1812
pubmed: 29697764
N Engl J Med. 2016 Sep 29;375(13):1221-30
pubmed: 27571011